CSI Market
Sign In | Register

Miragen Therapeutics Inc (MGEN) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access MGEN Annual Income Statement →
This income statement overview for Miragen Therapeutics Inc spans from Jun 30 2020 to Sep 30 2026, showing how the company's revenues, expenses, and earnings have changed across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MGEN/income-statements
https://api.csimarket.com/api/v1/companies/MGEN/fundamentals
https://api.csimarket.com/api/v1/companies/MGEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2026)
Q3 2026 		(Jun 30 2026) (Jun 30 2025) (Sep 30 2020) (Jun 30 2020)
Revenues
Sales of Products25.75
Total Revenue25.75
Costs & Expenses
Cost of Goods and Services Sold1.53
Gross Profit24.22
Selling, Administration, Marketing57.61
Depreciation & Amortization0.00
Research and Development Expense70.09
Total operating costs including COS0.00
Operating income / -loss-103.48
Interest Expense9.27
Interest Income9.54
Net Interest (-)Expense / Income0.26
Loss / -Gain on Investment9.54
Other loss / -income0.00
Total costs & expenses129.23
Income & Taxes
Income / -loss before income taxes-103.48
Income after income taxes0.00
Net income / -loss of other equity2.27
Income / -loss from continuing operations-101.21
Net income / -loss-101.21
Income / -loss to shareholder-101.21
EBIT0.00
EBITD0.00
EBITDA0.00
Earnings Per Share
Basic EPS (excl. extra items)0.00
Extraordinary items0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.00
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.00
4 historic quarters locked

Sign in to unlock the full Miragen Therapeutics Inc income statement history.

Sign In Create Free Account

About Viridian Therapeutics Inc De Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: November 4, 2026
  • Original filing: vrdn-20260930.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI